Fully human CD5 chimeric antigen receptor T cell injection Clinical Trials

1 actively recruiting trial

Top Sponsors

Institute of Hematology & Blood Diseases Hospital, China1

Indications

Relapsed and Refractory CD5 Hematological Tumors1
Cancer1

Other1 trial

CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors

N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.